ScholarLens Back to search
2019•Unpublished venueOpen access

BIOLOGICAL THERAPY ON RHEUMATOID VASCULITIS: A SYSTEMATIC REVIEW

Débora Patrícia Alves de Cerqueira, Ana Luísa Souza Pedreira, Marcelo Gomes Cerqueira

Open full text 3 citations

Abstract

Rheumatoid vasculitis (RV) is one of the most severe extra-articular manifestations of rheumatoid arthritis (RA). RV affects a subset of patients with established RA (approximately 2 to 5%). The morbidity and mortality of rheumatoid vasculitis are significant. Studies have shown that the 5-year mortality rate is 30% to 50% with high morbidities. For the treatment of mild rheumatoid vasculitis (affecting the skin and nerves) is typically treated with prednisone and methotrexate or azathioprine. Cases that are more serious may require treatment with higher-dose steroids and cyclophosphamide or biological agents. Aim: To describe the use of biological agents in the treatment of rheumatoid vasculitis, as well as to compare the efficacy and safety between these drugs.

Open-access reader

About this research paper

What this paper is about

Rheumatoid vasculitis (RV) is one of the most severe extra-articular manifestations of rheumatoid arthritis (RA). RV affects a subset of patients with established RA (approximately 2 to 5%). The morbidity and mortality of rheumatoid vasculitis are significant. Studies have shown that the 5-year mortality rate is 30% to 50% with high morbidities. For the treatment of mild rheumatoid vasculitis (affecting the skin and nerves) is typically treated with prednisone and methotrexate or azathioprine. Cases that are more serious may require treatment with higher-dose steroids and cyclophosphamide or biological agents. Aim: To describe the use of biological agents in the treatment of rheumatoid vasculitis, as well as to compare the efficacy and safety between these drugs.

Why it matters

OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Rheumatoid vasculitis (RV) is one of the most severe extra-articular manifestations of rheumatoid arthritis (RA). RV affects a subset of patients with established RA (approximately 2 to 5%). The morbidity and mortality of rheumatoid vasculitis are significant. Studies have shown that the 5-year mortality rate is 30% to 50% with high morbidities. For the treatment of mild rheumatoid vasculitis (affecting the skin and nerves) is typically treated with prednisone and methotrexate or azathioprine. Cases that are more serious may require treatment with higher-dose steroids and cyclophosphamide or biological agents. Aim: To describe the use of biological agents in the treatment of rheumatoid vasculitis, as well as to compare the efficacy and safety between these drugs.

Key concepts: Rheumatoid arthritis, Vasculitis, Azathioprine, Medicine, Cyclophosphamide, Methotrexate, Prednisone, Internal medicine

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
BIOLOGICAL THERAPY ON RHEUMATOID VASCULITIS: A SYSTEMATIC REVIEW — Research Paper | ScholarLens